Page 30 - Haematologica March 2020

S.L. Thein et al.
al. Anti-HI can cause a severe delayed
hemolytic transfusion reaction with hyper- hemolysis in sickle cell disease patients. Transfusion. 2016;56(7):1828-1833.
22. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syn- drome in children with sickle cell disease. Pediatrics. 2003;111(6 Pt 1):e661-665.
23. Michot JM, Driss F, Guitton C, et al. Immunohematologic tolerance of chronic transfusion exchanges with erythrocyta- pheresis in sickle cell disease. Transfusion. 2015;55(2):357-363.
24. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfu- sions. Transfusion. 2002;42(1):37-43.
25. Diamond WJ, Brown FL Jr, Bitterman P, Klein HG, Davey RJ, Winslow RM. Delayed hemolytic transfusion reaction presenting as sickle-cell crisis. Ann Intern Med. 1980;93(2): 231-234.
26. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49(9):1785- 1792.
27. Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340-1348.
28. Telen MJ, Afenyi-Annan A, Garrett ME, Combs MR, Orringer EP, Ashley-Koch AE. Alloimmunization in sickle cell disease: changing antibody specificities and associa- tion with chronic pain and decreased sur- vival. Transfusion. 2015;55(6 Pt 2):1378- 1387.
29. Carson JL, Triulzi DJ, Ness PM. Indications for and adverse effects of red-cell transfu- sion. N Engl J Med. 2017;377(13): 1261- 1272.
30. Yomtovian R, Kline W, Press C, et al. Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody. Lancet. 1984;1(8371):244-246.
31. Shaz BH, Stowell SR, Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood. 2011;117(5):1463-1471.
32. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101(2):454-462.
33. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest. 2006;116(6):1615- 1623.
34. Kapur R, Kim M, Rebetz J, Hallstrom B, et al. Gastrointestinal microbiota contributes to the development of murine transfusion- related acute lung injury. Blood Adv. 2018;2(13):1651-1663.
35. Semple JW, Rebetz J, Kapur R. Transfusion- associated circulatory overload and transfu- sion-related acute lung injury. Blood. 2019;133(17):1840-1853.
43. Dean CL, Maier CL, Roback JD, Stowell SR. Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive cri- sis in a patient with sickle cell disease. Transfusion. 2019;59(29):448-453.
44. Hauser RG, Hendrickson JE, Tormey CA. TRIX with treats: the considerable safety benefits of a transfusion medicine registry. Transfusion. 2019;59(8):2489-2492.
45. Mekontso Dessap A, Pirenne F, Razazi K, et al. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol. 2016;91(12):1181- 1184.
46. Hayes C, Shafi H, Mason H, Klapper E. Successful reduction of plasma free-hemo- globin using therapeutic plasma exchange: a case report. Transfus Apher Sci. 2016;54(2): 253-255.
47. Gardner K, Hoppe C, Mijovic A, Thein SL. How we treat delayed haemolytic transfu- sion reactions in patients with sickle cell disease. Br J Haematol. 2015;170(6):745-
36. Chapman CE, Stainsby D, Jones H, et al. Ten
years of hemovigilance reports of transfu-
sion-related acute lung injury in the United
Kingdom and the impact of preferential use
of male donor plasma. Transfusion. 2009;49 756.
(3):440-452.
37. Murphy MF, Navarrete C, Massey E. Donor
screening as a TRALI risk reduction strategy.
Transfusion. 2009;49(9):1779-1782.
38. Unni N, Peddinghaus M, Tormey CA, Stack
48. Karafin MS, Carpenter E, Pan A, Simpson P, Field JJ. Older red cell units are associated with an increased incidence of infection in chronically transfused adults with sickle cell disease. Transfus Apher Sci. 2017;56(3):345-
G. Record fragmentation due to transfusion 351.
at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion. 2014;54(1):98-103.
39. Harm SK, Yazer MH, Monis GF, Triulzi DJ, Aubuchon JP, Delaney M. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol. 2014;141(2):256-261.
40. Fasano RM, Branscomb J, Lane PA, Josephson CD, Snyder AB, Eckman JR. Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia. Transfus Med. 2019;29(3):185-192.
49. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062- 1064.
50. Chonat S, Quarmyne MO, Bennett CM, et al. Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2018;103(10):e483-e485.
51. Tong TN, Cen S, Branch DR. The monocyte monolayer assay: past, present and future. Transfus Med Rev. 2019;33(1):24-28.
52. Noizat-Pirenne F, Bachir D, Chadebech P, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2007;92(12):e132-
41. Stack G, Tormey CA. Detection rate of
blood group alloimmunization based on
real-world testing practices and kinetics of 135.
antibody induction and evanescence.
Transfusion. 2016;56(11):2662-2667.
42. Castro O, Oneal P, Medina A, Onojobi G, Gordeuk VR. Preventing delayed hemolytic transfusion reactions in sickle cell disease.
Transfusion. 2016;56(11):2899-2900.
53. Noizat-Pirenne F, Habibi A, Mekontso- Dessap A, et al. The use of rituximab to prevent severe delayed haemolytic transfu- sion reaction in immunized patients with sickle cell disease. Vox Sang. 2015;108(3): 262-267.
544
haematologica | 2020; 105(3)